AZN vs MLYS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AZN is the larger of the two ($272.37B market cap): the incumbent the market prices for continued execution (15.52x forward earnings, beta 0.16). MLYS is the smaller challenger ($1.24B), still expected to post a loss next year: more room to run, but more to prove. On the numbers, AZN leads on both counts: faster expected revenue growth (6% vs 0%) and expected profits next year, which MLYS does not have. The case for MLYS rests on its own driver (Lorundrostat FDA decision): if you believe in that, MLYS fits; if you believe in what the numbers show today, AZN does.
AZN vs MLYS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AZN | MLYS | What it tells you |
|---|---|---|---|
| Market cap | $272.37B | $1.24B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 15.52 | -5.76 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.16 | 0.82 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 37% of range | 1% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.27 | 2.46 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AZN and MLYS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and MLYS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and MLYS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does AstraZeneca (AZN) do?
AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.
What does Mineralys Therapeutics (MLYS) do?
Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by dysregulated aldosterone. Its lead and essentially only asset is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor being developed for uncontrolled and resistant hypertension, with additional programs exploring chronic kidney disease (CKD) and obstructive sleep apnea (OSA). The company completed its Phase 3 program (including the Launch-HTN and Advance-HTN trials) and submitted a New Drug Application that the FDA accepted, with a PDUFA target action date of December 22, 2026. As of its August update, commercial leadership was in place, initial sales territories had been identified, and the company expected its sales force to be built before that date.
AZN vs MLYS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
- MLYS drivers: Lorundrostat FDA decision; Large uncontrolled-hypertension market.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For MLYS, the dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe.
AZN or MLYS: which should you pick?
If the story you believe is AZN's (Oncology franchise and the $80 billion ambition), AZN is the more direct way to own it; if it is MLYS's (Lorundrostat FDA decision), MLYS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZN and MLYS guides.
AZN vs MLYS: the full fundamentals
AZN. AstraZeneca trades at about 25 times trailing reported earnings but about 15.5 times forward earnings, a gap that reflects heavy amortisation and one-off charges in reported profit and consensus for 2026 EPS near $10.12 rising to about $11.32 in 2027. The forward multiple has edged up from about 14.6 in October as the shares recovered, but it still sits near the low end of where a growth-oriented large-cap pharma usually trades, so the valuation reflects more caution about the 2032 patent cliff than enthusiasm for the $80 billion 2030 goal. Figures are approximate and tied to the asOf date; confirm live numbers before acting.
MLYS. Standard valuation multiples do not apply to Mineralys because it has no product revenue and posts ongoing losses funded by its cash balance. The roughly $1.2 billion market value, about 2 times its cash, down from about 2.8 times in October, reflects the market's probability-weighted view of lorundrostat's approval and future sales, not trailing fundamentals. The nine covering analysts rate it a strong buy with a mean target near $44, about three times the current price, though UBS cut its target to $19 in November, so the spread of views ahead of the December 22 decision is wide.
Headline figures (approximate, November 2026): AZN shows revenue (ttm) About $62.4 billion; Q3 2026 revenue about $16.2 billion, up roughly 7% year over year, net income (ttm) About $11.0 billion, a net margin near 18%, with gross margin near 82% and operating margin near 26%, eps Q3 2026 EPS $1.00 vs about $1.15 expected; trailing reported EPS about $7.07, p/e About 25x trailing reported earnings, about 15.5x forward; MLYS shows product revenue (ttm) ~$0 (pre-commercial), cash & investments ~$624.7M (September 30, 2026); runway guided into 2028, q3 2026 net loss ~$57.3M; EPS -$0.64 vs ~-$0.54 consensus, q3 2026 operating costs R&D ~$22.7M; G&A ~$37.4M (up from ~$9.7M on launch build).
The bottom line: AZN vs MLYS
AZN and MLYS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AZN and MLYS exposure against your real portfolio. It is not an investment adviser.
Wondering how AZN or MLYS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about AstraZeneca
Ask Walnut's AI anything about AZN and see how it fits what you own.
FAQ
What is the difference between AZN and MLYS?
+
AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by dysregulated aldosterone. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AZN or MLYS the better stock?
+
Neither is universally better. AZN is the larger incumbent; MLYS is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AZN or MLYS?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AZN and MLYS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AZN vs MLYS?
+
AZN: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. Generic and biosimilar erosion is already visible, with first generics to Farxiga cleared in 2026. Pipeline risk is constant, since late-stage trial failures such as a disappointing AVANZAR result can erase billions in expected value quickly. China, about a tenth of revenue, carries added uncertainty after the company's former China head was indicted in a compliance case that drew investor lawsuits. Drug pricing policy, US tariffs and currency swings add further volatility, and the balance sheet carries about $34 billion of debt against about $8 billion of cash. As a large-cap pharma the stock can still fall sharply on a single disappointing readout or regulatory decision, as its slide from a 52-week high near $213 to a low near $153 shows. The Q3 2026 EPS shortfall against consensus is a reminder that quarterly earnings can disappoint even as revenue grows. MLYS: The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash, has raised equity, and now carries about $98 million of debt, creating dilution and leverage risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to regulatory news: it fell about 32% in the month to November 20, 2026 and closed at $13.90, near its 52-week low of about $13.58, against a high of about $44.13.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AZN or MLYS; figures are approximate and dated (as of November 2026). Verify current data before investing.